HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vasopressin receptor antagonists: from pivotal trials to current practice.

Abstract
Heart failure is a growing health and economic problem in America, and outcomes continue to remain dismal, particularly for those presenting with acute heart failure syndrome (AHFS). In theory, arginine vasopressin antagonists (VRAs) could be useful in both acute and chronic heart failure, depending on which vasopressin receptor is targeted. Most studies of VRAs in heart failure have focused on V2 receptor antagonism, and to a lesser extent on combined V1a/V2 antagonism, due to the availability of appropriate agents and the unmet need of improving outcomes in AHFS. These agents are particularly attractive as adjunctive or alterative agents in AHFS because of their ability to produce a substantial diuresis without some of the drawbacks intrinsic to loop diuretics. While VRAs have been shown to ameliorate signs and symptoms of congestion when added to standard care, the largest trial of these agents showed no improvement in long-term morbidity, mortality, or hospitalization rates when added to standard care. This article reviews the mechanism of action of VRAs, the relevant clinical trials data, and current recommendations for clinical use, and suggests future directions for study of these agents in patients with heart failure.
AuthorsAnkur Kalra, Valmiki Maharaj, Steven R Goldsmith
JournalCurrent heart failure reports (Curr Heart Fail Rep) Vol. 11 Issue 1 Pg. 10-8 (Mar 2014) ISSN: 1546-9549 [Electronic] United States
PMID24197791 (Publication Type: Journal Article, Review)
Chemical References
  • Antidiuretic Agents
  • Antidiuretic Hormone Receptor Antagonists
  • Benzazepines
  • Hormone Antagonists
  • Arginine Vasopressin
  • Tolvaptan
Topics
  • Antidiuretic Agents (adverse effects, therapeutic use)
  • Antidiuretic Hormone Receptor Antagonists
  • Arginine Vasopressin (antagonists & inhibitors)
  • Benzazepines (therapeutic use)
  • Heart Failure (drug therapy)
  • Hormone Antagonists (adverse effects, therapeutic use)
  • Humans
  • Tolvaptan

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: